First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
First Patient Treated in Ph 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 25, 2024
First Patient Enrolled in FIERCE-HN Trial of Ficlatuzumab + ERBITUX® (cetuximab) in Patients with HPV-negative R/M HNSCC January 25, 2024
Enrollment opens for Ph 1b/2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer January 18, 2024
First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed January 18, 2024
First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer January 18, 2024
Patients enrolled into the 3rd Dosing Cohort of Ph 1/2 Study of ONCT-534 in R/R Metastatic CRPC January 10, 2024
23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded January 10, 2024
Status of Ph 1/2 Study of ONCT-808 in Patients with R/R Aggressive B-cell Lymphoma announced January 10, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
Investigator-initiated Ph 1/2 Trial of Seclidemstat + Azacitidine to Treat Heme Cancers Resumes Patient Enrollment January 10, 2024
Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML January 10, 2024
Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed January 10, 2024
First Patient Dosed in Trial Evaluating Efti and BAVENCIO in Metastatic Urothelial Cancer January 10, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
